Table 1 Characteristics of 81MM patients according to their HCV status
From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients
Items | No. of patients (%) | P value | |||
|---|---|---|---|---|---|
Ab (-)ve No. = 66 (81.5%) | Ab (+)ve/PCR (-)ve No. = 9 (11.1%) | Ab (+)ve/PCR (+)ve No. = 6 (7.4%) | |||
Age > 65 years | 3 (4.5%) | 2 (22.2%) | 0 (0.0%) | 0.095 | |
Gender | Male | 30 (45.5%) | 5 (55.6%) | 4 (66.7%) | 0.545 |
Female | 36 (54.5%) | 4 (44.4%) | 2 (33.3%) | ||
Serum M-protein: | |||||
FLC | 2 (3.0%) | 0 (0.0%) | 0 (0.0%) | 0.806 | |
IgAK | 3 (4.5%) | 0 (0.0%) | 0 (0.0%) | ||
IgAL | 1 (1.5%) | 0 (0.0%) | 0 (0.0%) | ||
IgGK | 50 (75.8%) | 9 (100.0%) | 6 (100.0%) | ||
IgGL | 10 (15.2%) | 0 (0.0%) | 0 (0.0%) | ||
ISS stage: | |||||
I | 14 (21.2%) | 0 (0.0%) | 0 (0.0%) | 0.114 | |
II | 24 (36.4%) | 7 (77.8%) | 3 (50.0%) | ||
III | 28 (42.4%) | 2 (22.2%) | 3 (50.0%) | ||
β2m ≥ 3.5 mg/L | 12 (25.5%) | 3 (37.5%) | 0 (0.0%) | 0.310 | |
Albumin < 3.5 g/L | 38 (58.5%) | 8 (88.9%) | 4 (66.7%) | 0.205 | |
Hemoglobin < 10 g/dL | 31 (47.0%) | 6 (66.7%) | 1 (16.7%) | 0.164 | |
Platelets < 100 × 109/L | 7 (10.6%) | 3 (33.3%) | 0 (0.0%) | 0.096 | |
Serum calcium ≥ 12.0 mg/dL | 51 (96.2%) | 9 (100.0%) | 5 (83.3%) | 0.762 | |
Serum creatinine ≥ 2.0 mg/dL | 58 (89.2%) | 6 (66.7%) | 6 (100.0%) | 0.100 | |
Response to MM treatment: | |||||
CR | 10 (15.2%) | 0 (0.0%) | 3 (50.0%) | 0.100 | |
VGPR | 10 (15.2%) | 0 (0.0%) | 0 (0.0%) | ||
PR | 23 (34.8%) | 7 (77.8%) | 2 (33.3%) | ||
PD | 13 (19.7%) | 1 (11.1%) | 0 (0.0%) | ||
ST | 10 (15.2%) | 1 (11.1%) | 1 (16.7%) | ||